

Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)

Technology appraisal guidance

Published: 9 March 2022

www.nice.org.uk/guidance/ta774

Contents

| | |
|------------------|---|
| Advice | 3 |
| Information..... | 3 |

Advice

NICE is unable to make a recommendation about the use in the NHS of lenalidomide for treating relapsed or refractory mantle cell lymphoma. This is because Celgene has confirmed that it does not intend to make an evidence submission for the appraisal. Celgene considers that the technology is unlikely to be used at this point in the treatment pathway.

Information

If NHS organisations wish to consider lenalidomide for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4476-7

Accreditation

